Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  talimogene laherparepvec
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, 2014-000185-22, NCT02263508
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201504731, NCI-2015-01193, 20139075, NCT02453191
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 20110266, NCI-2015-00229, 2014-001146-13, NCT02211131
Talimogene Laherparepvec in Treating Patients with Recurrent Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0034, NCI-2016-00199, NCT02658812
Talimogene Laherparepvec and Radiation Therapy in Treating Patients with Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10056, NCI-2016-01461, MC1678, NCT02923778
Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Stage III-IV Melanoma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1607, NCI-2016-01698, NCT02965716
Safety Study of Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma and Metastatic Liver Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20140318, NCI-2015-02069, 2014-005386-67, NCT02509507
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-034)
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20130232, NCI-2016-00537, 20130232 / KEYNOTE-034, NCT02626000
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and under
Trial IDs: 20110261, NCI-2016-00868, 2015-003645-25, NCT02756845
Start Over